Paradigm Biopharmaceuticals Limited (ASX:PAR – Get Free Report) insider Matthew Fry bought 150,000 shares of Paradigm Biopharmaceuticals stock in a transaction dated Thursday, October 10th. The stock was purchased at an average price of A$0.20 ($0.14) per share, with a total value of A$30,450.00 ($20,300.00).
Paradigm Biopharmaceuticals Price Performance
The company has a debt-to-equity ratio of 1.00, a current ratio of 7.22 and a quick ratio of 5.93.
Paradigm Biopharmaceuticals Company Profile
Read More
- Five stocks we like better than Paradigm Biopharmaceuticals
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- The Risks of Owning Bonds
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Retail Stocks Investing, Explained
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Paradigm Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paradigm Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.